

Shang-Gin Wu

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1863765/shang-gin-wu-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

36
papers

1,363
citations

20
h-index

36
g-index

37
ext. papers

1,736
ext. citations

6.3
avg, IF

5.01
L-index

#	Paper	IF	Citations
36	Prognostic significance of dynamin-related protein 1 expression in advanced lung adenocarcinoma.. <i>Pathology Research and Practice</i> , 2022 , 234, 153931	3.4	
35	Multi-kinase framework promotes proliferation and invasion of lung adenocarcinoma through activation of dynamin-related protein 1. <i>Molecular Oncology</i> , 2021 , 15, 560-578	7.9	2
34	Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With Mutation in East Asian Populations: A Single-Center Cohort Study in Taiwan. <i>JTO Clinical and Research Reports</i> , 2021 , 2, 100140	1.4	2
33	MiR-200c-3p suppression is associated with development of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer via a mediating epithelial-to-mesenchymal transition (EMT) process. <i>Cancer Biomarkers</i> , 2020 , 28, 351-363	3.8	8
32	Complex EGFR mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall survival in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2020 , 145, 1-9	5.9	9
31	miR-146b-5p Enhances the Sensitivity of NSCLC to EGFR Tyrosine Kinase Inhibitors by Regulating the IRAK1/NF- κ B Pathway. <i>Molecular Therapy - Nucleic Acids</i> , 2020 , 22, 471-483	10.7	9
30	The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920946156 ^t	5.4	3
29	An Observational Study of Acquired T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan. <i>Frontiers in Oncology</i> , 2020 , 10, 1481	5.3	7
28	Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signaling in lung cancer. <i>International Journal of Cancer</i> , 2019 , 145, 1609-1624	7.5	19
27	MicroRNA in Lung Cancer Metastasis. <i>Cancers</i> , 2019 , 11,	6.6	39
26	High throughput sequencing of T-cell receptor repertoire using dry blood spots. <i>Journal of Translational Medicine</i> , 2019 , 17, 47	8.5	9
25	IGFBP7 Drives Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition in Lung Cancer. <i>Cancers</i> , 2019 , 11,	6.6	8
24	Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. <i>Molecular Cancer</i> , 2018 , 17, 38	42.1	253
23	Driver mutations of young lung adenocarcinoma patients with malignant pleural effusion. <i>Genes Chromosomes and Cancer</i> , 2018 , 57, 513-521	5	9
22	Upregulation of microRNA-137 expression by Slug promotes tumor invasion and metastasis of non-small cell lung cancer cells through suppression of TFAP2C. <i>Cancer Letters</i> , 2017 , 402, 190-202	9.9	37
21	A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population. <i>Lung Cancer</i> , 2017 , 103, 82-89	5.9	31
20	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non-Small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017 , 18, 324-332.e1	4.9	26

19	Lung adenocarcinoma patients of young age have lower mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors. <i>ERJ Open Research</i> , 2017 , 3,	3.5	21
18	IGFBP-7 to confer resistance to the epidermal growth factor receptor tyrosine kinase inhibitor.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e20572-e20572	2.2	
17	The Role of PIK3CA Mutations among Lung Adenocarcinoma Patients with Primary and Acquired Resistance to EGFR Tyrosine Kinase Inhibition. <i>Scientific Reports</i> , 2016 , 6, 35249	4.9	24
16	Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 1140-52	8.9	46
15	The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients. <i>Oncotarget</i> , 2016 , 7, 12404-13	3.3	165
14	Association of BIM Deletion Polymorphism With Intrinsic Resistance to EGFR Tyrosine Kinase Inhibitors in Patients With Lung Adenocarcinoma. <i>JAMA Oncology</i> , 2016 , 2, 826-8	13.4	16
13	EGFR-L858R mutant enhances lung adenocarcinoma cell invasive ability and promotes malignant pleural effusion formation through activation of the CXCL12-CXCR4 pathway. <i>Scientific Reports</i> , 2015 , 5, 13574	4.9	28
12	IL-8 confers resistance to EGFR inhibitors by inducing stem cell properties in lung cancer. <i>Oncotarget</i> , 2015 , 6, 10415-31	3.3	49
11	Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion. <i>Lung Cancer</i> , 2015 , 88, 208-14	5.9	41
10	Clinical and the prognostic characteristics of lung adenocarcinoma patients with ROS1 fusion in comparison with other driver mutations in East Asian populations. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 1171-9	8.9	57
9	Frequent EGFR mutations in nonsmall cell lung cancer presenting with miliary intrapulmonary carcinomatosis. <i>European Respiratory Journal</i> , 2013 , 41, 417-24	13.6	30
8	Survival of lung adenocarcinoma patients with malignant pleural effusion. <i>European Respiratory Journal</i> , 2013 , 41, 1409-18	13.6	68
7	EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 98-104	8.9	76
6	Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations. <i>Lung Cancer</i> , 2011 , 72, 333-9	5.9	37
5	Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction. <i>PLoS ONE</i> , 2011 , 6, e23303	3.7	38
4	Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011 , 183, 1071-9	10.2	129
3	Pericardial pigtail knotting. <i>European Journal of Cardio-thoracic Surgery</i> , 2011 , 39, 790	3	2
2	Successful weaning after plasma exchange for polyneuropathy related to POEMS syndrome. <i>Journal of Clinical Apheresis</i> , 2009 , 24, 170-2	3.2	

- 1 Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern. *Oncologist*, **2008**, 13, 1276-84 5·7 64